Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria

Richter, Leo; Vujic, Igor; Sesti, Alma; Itzinger-Monshi, Babak; Sanlorenzo, Martina; Posch, Christian; Rappersberger, Klemens

doi:10.1111/ddg.13191

Cited by 10 publications

(9 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, it might be more useful for the clinician than the mere comparison of PASI score changes during treatment. Psoriasis drugs are usually discontinued for three reasons: lack of primary efficacy, loss of efficacy and AEs . More than half of our patients discontinued apremilast treatment, and most did so because of the lack of primary efficacy.…”

Section: Discussionmentioning

confidence: 91%

“…Patients with mild disease can often be treated efficiently with topical preparations; however, those with moderate to severe disease require systemic therapies including photo (chemo) therapy with UVA and UVB, fumaric acid esters, retinoids, methotrexate, cyclosporine, or newer biologic agents (biologics) and their biosimilars . Such biologics have changed the therapeutic landscape, and most patients benefit greatly from these new modalities . Still, not all patients respond to such systemic antipsoriasis therapies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Apremilast in psoriasis – a prospective real‐world study

Vujic

Herman

Sanlorenzo

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Apremilast in psoriasis – a prospective real‐world study

Vujic

Herman

Sanlorenzo

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…However, this was estimated in a multivariable model, in which sex was not being studied as the main exposure, thus it should be interpreted with caution (26). Similarly, Richter et al (27) identified male sex as a positive predictor of longer adalimumab survival in psoriasis, and Pogácsás et al (28) observed more long-term survival of TNF-alpha inhibitors and ustekinumab amongst men in a Hungarian cohort. Given the differences in methodologies, further prospective studies should be carried out to measure the impact of sex on the effectiveness of systemic therapies.…”

Section: Discussionmentioning

confidence: 99%

Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort

Hernández-Fernández

Carretero²,

Rivera³

et al. 2021

Acta Derm Venereol

View full text Add to dashboard Cite

The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to determine, in a large group of 2,881 patients followed from January 2008 to November 2018, whether sex influences prescription, effectiveness of therapy, or the risk of adverse events. The results show that women were more likely than men to be prescribed systemic therapy. No differences between men and women were found in the effectiveness of therapy. Women were also more likely to experience adverse events, but the difference in risk is small, and does not justify different management. The effect of sex on systemic therapy for psoria sis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be pre scribed biologics. There were no differences between men and women in effectiveness of therapy, measur ed in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness.

show abstract

“…Clinical outcomes (mainly PASI) were reported in 75% of prospective studies [27, 39, 47-53], in about 50% of prospective registries [20, 24, 54-61] and retrospective studies [29, 30, 32, 34, 37, 62-70], and in no retrospective administrative databases/claims. Drug survival of biological therapies was reported in over 60% of prospective registries [14, 20, 21, 24, 25, 31, 54, 57, 71-74], retrospective studies [18, 19, 22, 23, 26, 29, 30, 32, 34, 37, 38, 68, 70, 75-77] and administrative databases/claims [28, 35, 36, 40-42, 46], and less frequently (33%) in prospective studies [27, 33, 52, 78]. Subanalyses on reasons of discontinuation, such as switching, dose augmentation, or biological therapy restarting, were scanty.…”

Section: Resultsmentioning

confidence: 99%

Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival

Costanzo¹,

Malara²,

Pelucchi³

et al. 2018

Dermatology

View full text Add to dashboard Cite

Psoriasis is a complex and chronic disease, and, in most cases, therapies are required during all patients’ lifetime. The efficacy and safety profiles of biological therapies are well established, but their effectiveness is still open to discussion. We performed a systematic review to summarize how the effectiveness of biological therapies for psoriasis is measured in real-world studies and to understand whether drug survival, a recent alternative outcome to clinical ones, is a recurrent and valid outcome of effectiveness. In March 2017, we searched for quantitative epidemiological data of psoriasis treatments using PubMed/Medline and EMBASE, and we included 65 publications. The retrospective study design (37%) was most frequent, followed by prospective registries (29%), prospective studies (19%), and retrospective administrative databases/claims. Drug survival was reported in over 60% of prospective registries and retrospective studies, and less frequently in prospective studies. A general consensus emerged in the definition of drug survival as the time patients remain under treatment with a specific therapy, and in its interpretation as an overall marker of treatment success and treatment adherence, as it represents simultaneously information on drug efficacy, drug safety, and patient satisfaction. In conclusion, notwithstanding some limitations, drug survival is a useful measurement of biological therapy effectiveness for psoriasis in daily practice. Its major advantage is that it can be computed also in already collected databases without any specific clinical information on psoriasis. This outcome, combined with evidence on clinical markers of effectiveness, can contribute to better understanding the performance of this expensive class of drugs.

show abstract

Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria

Abstract: Most AEs occur during the first year of treatment. Adalimumab and ustekinumab are marked by longer drug survival compared to etanercept.

Cited by 10 publications

References 46 publications

Apremilast in psoriasis – a prospective real‐world study

Apremilast in psoriasis – a prospective real‐world study

Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort

Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival

Contact Info

Product

Resources

About